Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bridging The Drug Price Divide: Ideas And Approaches Debated At PSA

Executive Summary

Leaders from across the industry met at Informa's Pharmaceutical Strategy conference and addressed some of the most critical issues facing the industry: pharma's tarnished reputation and drug pricing.

You may also be interested in...



US Drug Spending: Where Does All The Money Go?

PhRMA has released new data on where gross and net drug expenditure ends up along the pharmaceutical supply chain, which will support its position the debate over US drug pricing.

Drug Pricing ‘Biggest Offenders’ Are Annual Increases On Widely Used Brands

Express Scripts Chief Medical Officer Steve Miller suggests that caps on annual price increases could significantly ease payer concerns over drug pricing.

Pharma CEOs Tackle A Tough Question: “Why Don’t People Like You?”

Pfizer CEO Ian Read, Regeneron CEO Leonard Schleifer, Gilead CEO John Milligan and Lilly’s incoming CEO David Ricks discussed pharma’s reputation problem during the Forbes Healthcare Summit.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097422

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel